Peripheral Biomarker Based Combinatorial Early Diagnostics for Dementia (CombiDiag)

基于外周生物标志物的痴呆症组合早期诊断 (CombiDiag)

• 批准号: EP/X025578/1
• 负责人: Genhua Pan
• 金额: $ 33.8万
• 依托单位: Plymouth University
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=EP%2FX025578%2F1
• 关键词: Peripheral; Biomarker; Based; Combinatorial; Early

CombiDiag DN aims to develop an AI-data-driven peripheral biomarker based combinatorial diagnostic protocol for early stages of Alzheimers disease (AD), a major form of dementia, and to train a new generation of fellows for this interdisciplinary field. Dementia, a devastating disease of older age, is the challenge of our lifetime and one of the Societal Challenges listed by the UN Sustainable Development Goals and Horizon Europe. CombiDiag responds to this challenge to establish a much-needed DN to carry out an integrated study of minimally invasive and cost-effective peripheral biomarkers, including body fluid markers from blood, urine and saliva, and digital markers from speech, motor functions and sleep for developing the combinatorial early AD diagnostics. The consortium comprises nine academic and eight non-academic institutions across Europe, USA, Canada, and China. It synergises leading academic and industrial experts worldwide to build a triple-i research and training platform for the training of a new generation of Fellows to take early AD diagnostic research to a new level. Fellows will be trained under the Vitae Researcher Development Framework innovatively combined with the CombiDiag platform for triple-i scientific and transferable skills as well as personal quality, creative thinking, and business mind-set. The DN has a highly innovative research programme for the discovery of peripheral AD biomarkers, detection techniques, AI/data driven technology, clinical validation, and integration into trial designs. The advances in CombiDiag research will enable a case finding tool at primary care level for helping achieve improved drug discoveries, disease-modifying treatments, preventive strategies and care provision for AD. CombiDiag will deliver 10 highly-skilled, creative and entrepreneurial Fellows, setting them on a path to successful careers in academia or industry to ensure that the medical and societal challenges imposed by AD are met.

CombiDiag DN旨在开发一种基于AI数据驱动的外周生物标志物的组合诊断方案，用于阿尔茨海默病（AD）的早期阶段，AD是痴呆的一种主要形式，并为这一跨学科领域培养新一代研究员。老年痴呆症是一种毁灭性的老年疾病，是我们一生的挑战，也是联合国可持续发展目标和地平线欧洲列出的社会挑战之一。CombiDiag应对这一挑战，建立了一种急需的DN，以进行微创且具有成本效益的外周生物标志物的综合研究，包括来自血液、尿液和唾液的体液标志物，以及来自言语、运动功能和睡眠的数字标志物，以开发组合早期AD诊断。该联盟由欧洲、美国、加拿大和中国的9个学术机构和8个非学术机构组成。它协同全球领先的学术和工业专家，建立了一个三i研究和培训平台，用于培训新一代研究员，将早期AD诊断研究推向新的水平。研究员将在Vitae研究员发展框架下接受培训，该框架与CombiDiag平台创新地结合在一起，用于三i科学和可转移技能以及个人素质，创造性思维和商业心态。DN拥有高度创新的研究计划，用于发现外周AD生物标志物，检测技术，AI/数据驱动技术，临床验证和整合到试验设计中。CombiDiag研究的进展将使初级保健水平的病例发现工具能够帮助实现改善药物发现，疾病改善治疗，预防策略和AD护理提供。CombiDiag将提供10名高技能，创造力和创业精神的研究员，使他们在学术界或工业界成功的职业生涯，以确保AD所带来的医疗和社会挑战得到满足。